Rates of HIV-associated dementia have decreased from approximately 50% in the pre-cART era to 2% currently. However, roughly 50% of patients treated with cART have the milder forms of HIV-associated neurocognitive disorder (HAND).
A scientific statement from the American Heart Association was published in Circulation, with the purpose of providing a thorough review of available evidence on HIV-associated cardiovascular disease.
This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
Focused prevention and treatment of noncommunicable diseases may reduce the burden of multimorbidity in people living with HIV who have mood disorders and multimorbidity.
A long-acting therapy may be noninferior to the current daily oral antiretroviral therapy (ART) in maintaining viral suppression in the treatment of HIV-1 infection.
Patients with HIV and those with a history of intravenous drug use may have significantly higher rates of hepatic steatosis, according to research results presented at the virtual Conference on Retroviruses and Opportunistic Infections, held from March 8 to 11, 2020. Two groups of researchers examined the role of hepatic steatosis across these patient populations.…
The transmission of direct-acting antiviral (DAA) resistance-associated substitutions (RAS) may inhibit hepatitis C virus (HCV) cure rates and elimination efforts.
Results from the DUALIS study demonstrated that dual therapy with dolutegravir and boosted darunavir tended to be an effective treatment option with no treatment-emergent resistance for people with HIV.
Dolutegravir (DTG)-based regimen may lead to significant improvement in blood lipid concentration, and no interference on glucose metabolism, but a relevant increase in trunk fat without alterations of body mass index (BMI) and body fat percent among youth with HIV. The results of this research were presented at the virtual Conference on Retroviruses and Opportunistic…
Therapy with monthly injection of long-acting cabotegravir plus rilpivirine was noninferior to once-daily oral therapy for maintaining HIV-1 suppression.
Among patients coinfected with HIV/HCV, there were no medium-term beneficial effects of sustained virologic response on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.
